Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04461119 · ClinicalTrials.gov registry record · Phase 2
Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia
A Phase 2 study, sponsored by Newron Pharmaceuticals SPA.
- Completed
- Registry status
- Phase 2
- Development phase
- 138
- Enrollment target
NCT04461119 is a Phase 2 study that has completed, run by Newron Pharmaceuticals SPA. The registered enrollment target is 138 participants.
The verdict
NCT04461119, a Phase 2 study, has completed, sponsored by Newron Pharmaceuticals SPA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 138 participants
- Enrollment target
Study Summary
This 4-week study will evaluate the safety, tolerability and preliminary evidence of efficacy of evenamide (7.5,and 15 mg and placebo, bid) treatment in outpatients with chronic schizophrenia.
Interventions
- DRUG Placebo
- DRUG Evenamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2020-06-16 |
| Est. Completion | 2021-03-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04461119
The ClinicalTrials.gov registry entry for NCT04461119 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Newron Pharmaceuticals SPA, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04461119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04461119 about?
NCT04461119 is a clinical study titled "Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia". This 4-week study will evaluate the safety, tolerability and preliminary evidence of efficacy of evenamide (7.5,and 15 mg and placebo, bid) treatment in outpatients with chronic schizophrenia.
What is the current status of trial NCT04461119?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 138 participants. The study started on 2020-06-16. Estimated completion is 2021-03-13.
What interventions are being tested in trial NCT04461119?
The interventions under investigation include: Placebo (DRUG), Evenamide (DRUG).
Who is sponsoring clinical trial NCT04461119?
This trial is sponsored by Newron Pharmaceuticals SPA, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.